Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Here's What Key Metrics Tell Us About Vertex (VERX) Q2 Earnings
10:31am, Wednesday, 06'th Aug 2025
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es
Vertex (VERX) Q2 Earnings and Revenues Surpass Estimates
09:21am, Wednesday, 06'th Aug 2025
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Announces Second Quarter 2025 Financial Results
07:05am, Wednesday, 06'th Aug 2025
KING OF PRUSSIA, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
04:42am, Wednesday, 06'th Aug 2025
Vertex Pharmaceuticals (VRTX -20.61%) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
01:58pm, Tuesday, 05'th Aug 2025
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
10:25am, Tuesday, 05'th Aug 2025
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with
Vertex tops estimates on cystic fibrosis treatment strength, new products
05:40pm, Monday, 04'th Aug 2025
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates
04:59pm, Monday, 04'th Aug 2025
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat
04:35pm, Monday, 04'th Aug 2025
Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
01:48pm, Monday, 04'th Aug 2025
Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4.
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Wednesday, 30'th Jul 2025
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
10:16am, Tuesday, 29'th Jul 2025
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Monday, 28'th Jul 2025
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The 3 Things That Matter for Vertex Pharmaceuticals Now
07:15am, Monday, 28'th Jul 2025
Vertex Pharmaceuticals (VRTX -0.57%) has been a terrific stock to own over the past decade. The stock has outperformed the market over this period, thanks to consistent financial results and excellent
Vertex (VERX) Moves 5.0% Higher: Will This Strength Last?
01:16pm, Tuesday, 15'th Jul 2025
Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
